Contribute Try STAT+ Today

While large pharmaceutical companies have been reporting failure after expensive failure in their efforts to develop an Alzheimer’s drug by targeting amyloid, a growing number of startups have been quietly trying different strategies. One approach, pioneered by South San Francisco-based Cortexyme, is based on an old idea that is gaining traction after being shunted aside for decades: that an infectious agent causes Alzheimer’s, and that targeting that pathogen and the neuronal havoc it wreaks can stop and even reverse some aspects of the disease.

Proponents of the amyloid hypothesis — that clumps of this protein fragment cause the disease and that eliminating them can stop or reverse it — “have led this field astray for 30 years” said Cortexyme co-founder and CEO Casey Lynch in an email. “Unfortunately, the influence of the few and the groupthink is continuing.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Elsewhere, studies have invoked other organisms eg herpes and fungi …

    If this is so, and the infective hypothesis holds, then Alzheimer’s Disease may be at a common end pathway of several different infections, with inflammation being a common feature leading to neurodegeneration and death ..

    Thus only inhibition of P gingivalis toxins may not address the whole AD population in the clinical studies ..

    Immunomodulation, antiinflammation and neuroregeneration may thus offer more broadcast therapeutic intervention

  • This well-written report from Sharon Begley is timely now that Cortexyme has come out of stealth mode. Let’s hope their trial results are promising, but kudos to the company for trying something other than the traditional anti-amyloid approach. The role of other microbes found in brains must also be elucidated. Fortunately, the NIA has recently elevated “pathogens in Alzheimer’s” to “high priority” for research grants, and likely has millions of dollars to award to worthy proposals.

Comments are closed.